All In Biotech

Drug Trial Radar · NCT03547167

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)

A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)

Last checked: Nov 19, 2026Latest source record: Jan 15, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,515 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,515

Actual

Start

Jul 16, 2018

Primary completion

Jan 20, 2020

Study completion Jan 20, 2020

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jun 6, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 49 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is designed to 1) describe the safety, tolerability, and immunogenicity of V114 and Prevnar 13™ in pneumococcal vaccine-naïve adults at increased risk for pneumococcal disease and to 2) describe the safety, tolerability, and immunogenicity of PNEUMOVAX™23 when administered 6 months after receipt of either V114 or Prevnar 13™. Increased risk for pneumococcal disease is defined as 1) an underlying medical condition, 2) behavioral habits such as smoking or alcohol use, or 3) living in a community/environment with increased risk of disease transmission.

Conditions

  • Pneumococcal Infections

Interventions

  • V114Biological

    15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose

  • Prevnar 13™Biological

    13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg), and aluminum phosphate adjuvant (125 mcg aluminum) in each 0.5 ml dose

  • PNEUMOVAX™23Biological

    23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Solicited Injection-site Adverse Events Following V114 or Prevnar 13™Time frame: Up to 5 days after Vaccination 1
  2. Percentage of Participants With Solicited Systemic Adverse Events Following V114 or Prevnar 13™Time frame: Up to 14 days after Vaccination 1
  3. Percentage of Participants With a Vaccine-related Serious Adverse Event Following V114 or Prevnar 13™Time frame: Up to Month 6 (before Vaccination 2)
  4. Geometric Mean Titer of Serotype-specific Opsonophagocytic Activity Day 30 Following V114 or Prevnar 13™Time frame: Day 30

Locations

78 sites in 7 countries. Site status is shown where the registry gives one.

  • Chinle Comprehensive Health Care Facility ( Site 0001)

    Chinle, Arizona

  • Fort Defiance Center for American Indian Health ( Site 0002)

    Fort Defiance, Arizona

  • Pulmonary Associates, PA ( Site 0043)

    Glendale, Arizona

  • Central Phoenix Medical Clinic, LLC ( Site 0031)

    Phoenix, Arizona

  • Whiteriver Center for American Indian Health ( Site 0005)

    Whiteriver, Arizona

  • Inland Empire Clinical Trials, LLC ( Site 0052)

    Rialto, California

  • Top Medical Research, Inc ( Site 0033)

    Cutler Bay, Florida

  • Indago Research & Health Center, Inc ( Site 0054)

    Hialeah, Florida

  • Renstar Medical Research ( Site 0008)

    Ocala, Florida

  • Triple O Research Institute, P.A. ( Site 0026)

    West Palm Beach, Florida

  • Emory University School of Medicine at Grady Hospital ( Site 0027)

    Atlanta, Georgia

  • Kootenai Health ( Site 0042)

    Coeur d'Alene, Idaho

  • Evanston Premier Healthcare & Research, LLC. ( Site 0012)

    Evanston, Illinois

  • Pharmakon Inc ( Site 0049)

    Evergreen Park, Illinois

  • Reid Physician Associates ( Site 0055)

    Richmond, Indiana

  • The Center for Pharmaceutical Research PC ( Site 0050)

    Kansas City, Missouri

  • Clinical Research Consortium ( Site 0053)

    Las Vegas, Nevada

  • Internal Medicine Associates [Bridgeton, NJ] ( Site 0015)

    Bridgeton, New Jersey

  • Gallup Center for American Indian Health ( Site 0003)

    Gallup, New Mexico

  • Shiprock Center for American Indian Health ( Site 0004)

    Shiprock, New Mexico

  • Corning Center For Clinical Research ( Site 0036)

    Corning, New York

  • Mid Hudson Medical Research ( Site 0022)

    New Windsor, New York

  • Wake Research Associates, LLC ( Site 0016)

    Raleigh, North Carolina

  • Lehigh Valley Health Network ( Site 0040)

    Allentown, Pennsylvania

  • University of Pennsylvania ( Site 0030)

    Philadelphia, Pennsylvania

  • Mountain View Clinical Research ( Site 0007)

    Greer, South Carolina

  • Holston Medical Group ( Site 0025)

    Kingsport, Tennessee

  • AIM Trials ( Site 0060)

    Fort Worth, Texas

  • University of Texas Medical Branch at Galveston ( Site 0034)

    Galveston, Texas

  • Private Practice Leadership, LLC ( Site 0051)

    Houston, Texas

  • Texas Center For Drug Development ( Site 0041)

    Houston, Texas

  • Texas Institute Of Cardiology ( Site 0048)

    McKinney, Texas

  • Village Health Partners ( Site 0006)

    Plano, Texas

  • Copperview Medical Center ( Site 0038)

    South Jordan, Utah

  • Timber Lane Allergy & Asthma Research, LLC ( Site 0044)

    South Burlington, Vermont

  • Pulmonary & Sleep Research ( Site 0046)

    Spokane Valley, Washington

  • Gundersen Health System ( Site 0021)

    La Crosse, Wisconsin

  • Marshfield Clinic ( Site 0013)

    Marshfield, Wisconsin

  • Paratus Clinical Kanwal ( Site 0172)

    Kanwal, Australia

  • Nepean Hospital ( Site 0176)

    Kingswood, Australia

Showing 40 of 78 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.